SecuraBio

[SecuraBio @SecuraBio]

https://t.co/vZR9upgzoV

[SecuraBio @SecuraBio]

Secura Bio Provides Corporate Update and Highlights Progress in its Phase 3 TERZO Study https://t.co/64vgd7Z7eo

[SecuraBio @SecuraBio]

https://t.co/oHGT0ENiSi

[SecuraBio @SecuraBio]

https://t.co/1JRyjNWUWS

[SecuraBio @SecuraBio]

We are excited to welcome Dr. Patrick Vink as Chairman of the Board of Directors of Secura Bio, Inc.!
https://t.co/tVBmNi7pCP

[SecuraBio @SecuraBio]

We are thrilled to welcome Chip Romp as our new CEO. Stay tuned for more company news under Chip’s leadership.
https://t.co/heCukmyBhV

[SecuraBio @SecuraBio]

Secura Bio, Inc. Receives Orphan Drug Designation in Europe for Duvelisib for the Treatment of Patients with Perip... https://t.co/F0lrykxWgE

[SecuraBio @SecuraBio]

https://t.co/2k05fVZxkP

[SecuraBio @SecuraBio]

https://t.co/zZfbZbtpAQ

[SecuraBio @SecuraBio]

COPIKTRA® (duvelisib) receives European Union Marketing Authorization for the Treatment of Relapsed or Refractory CLL and Refractory FL https://t.co/8C7xtxl3lR

[SecuraBio @SecuraBio]

Secura Bio Acquires Global Rights to Farydak https://t.co/s6So0pJ7Vo